Moustafa Abohawya

@abohawya.bsky.social

Postdoc interested in #Cancer #Resistence #Organoids #CRISPR screens and #Bioinformatics. Egyptian 🇪🇬 living in Dresden 🇩🇪

More people younger than 50 are being diagnosed with colorectal cancer, and the disease is often more aggressive in this age group. A single-cell study of colorectal tumors reveals differences in cell composition and expression in tumors from younger patients.

Study reveals distinct cellular and genetic differences in colorectal cancer in younger patients

Researchers identified age-associated differences in tumor composition and gene activity, creating a foundation for investigating why colorectal cancer can be more aggressive in younger adults.

broad.io

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://nej.md/4nWaxvM #ASCO26

Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.